| 12428411 |
Preparation of oxindole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors |
Jianming Bao, James P. Roane |
2025-09-30 |
|
| 12414952 |
Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use |
Zachary G. Brill, Amjad Ali, Jared N. Cumming, Duane DeMong, Qiaolin Deng +10 more |
2025-09-16 |
|
| 12410159 |
Preparation of oxindole derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors |
Jianming Bao, James P. Roane |
2025-09-09 |
|
| 11976061 |
Preparation of benzimidazolone derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors |
Eric R. Ashley, Jianming Bao, Chen Cheng, James P. Roane, Emma Helen Southgate |
2024-05-07 |
$308,626,000 |
| 11787810 |
Diacylglyceride O-acyltransferase 2 inhibitors |
Cedric Lorenz Hugelshofer, Victor W. Mak, James P. Roane, Jillian R. Sanzone, Samantha E. Shockley +1 more |
2023-10-17 |
$465,804,000 |
| 11498923 |
Substituted imidazo[1,2-c]quinazolines as A2A antagonists |
Gioconda V. Gallo-Etienne, Joseph M. Kelly, Michael Y. Berlin, Pauline C. Ting, Hongwu Wang |
2022-11-15 |
$883,400,000 |
| 11046714 |
2,2-difluorodioxolo A2A receptor antagonists |
Ali Amjad, Gioconda V. Gallo, Timothy J. Henderson, Rongze Kuang, Michael Man-Chu Lo +6 more |
2021-06-29 |
$135,073,000 |
| 10822338 |
Substituted aminoquinazoline compounds as A2A antagonist |
Amjad Ali, Xianhai Huang, Rongze Kuang, Heping Wu, Rajan Anand +6 more |
2020-11-03 |
$132,407,000 |
| 10472347 |
Aminopyrazine compounds with A2A antagonist properties |
Rongze Kuang, Pauline C. Ting, Amjad Ali, Heping Wu, Michael Y. Berlin +6 more |
2019-11-12 |
$187,990,000 |
| 10344039 |
Macrocyclic spirocarbamate derivatives as factor XIa inhibitors, pharmaceutically acceptable compositions and their use |
Amjad Ali, Jiayi Xu, Wei Zhou |
2019-07-09 |
$88,734,000 |
| 10214512 |
Factor XIA inhibitors |
Jiayi Xu, Amjad Ali, Wei Zhou, Ying-Duo Gao, Scott D. Edmondson +9 more |
2019-02-26 |
$65,822,000 |
| 10138212 |
Aminoquinazoline compounds as A2A antagonist |
Amjad Ali, Rongze Kuang, Michael Man-Chu Lo, Pauline C. Ting, Purakkattle Biju +21 more |
2018-11-27 |
$94,550,000 |
| 10093683 |
Factor XIa inhibitors |
Zhuyan Guo, Amjad Ali, Scott D. Edmondson, Weiguo Liu, Gioconda V. Gallo-Etienne +16 more |
2018-10-09 |
$288,663,000 |
| 10011615 |
Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with A2A anatagonist properties |
Amjad Ali, Michael Man-Chu Lo, Andrew Stamford, Rongze Kuang, Paul Tempest +14 more |
2018-07-03 |
$73,356,000 |
| 9708347 |
Heterobicyclo-substituted [1,2,4]triazolo[1,5-C]quinazolin-5-amine compounds with A2A antagonist properties |
Amjad Ali, Michael Man-Chu Lo |
2017-07-18 |
$61,300,000 |
| 9676780 |
Piperazine-substituted [1,2,4]triazolo[1,5-C]quinazolin-5-amine compounds with A2A antagonist properties |
Amjad Ali, Michael Man-Chu Lo, Andrew Stamford, Rongze Kuang, Paul Tempest +19 more |
2017-06-13 |
$92,938,000 |
| 8524697 |
C20-C21 substituted glucocorticoid receptor agonists |
John C. Anthes, Kevin D. McCormick, John Hey, Robert G. Aslanian, Purakkattle Biju +5 more |
2013-09-03 |
$73,082,000 |
